MD4635C1 - Compuşi de chinolină substituiţi selectiv - Google Patents

Compuşi de chinolină substituiţi selectiv Download PDF

Info

Publication number
MD4635C1
MD4635C1 MDA20160052A MD20160052A MD4635C1 MD 4635 C1 MD4635 C1 MD 4635C1 MD A20160052 A MDA20160052 A MD A20160052A MD 20160052 A MD20160052 A MD 20160052A MD 4635 C1 MD4635 C1 MD 4635C1
Authority
MD
Moldova
Prior art keywords
selectively substituted
substituted quinoline
quinoline compounds
tlr
sle
Prior art date
Application number
MDA20160052A
Other languages
English (en)
Russian (ru)
Other versions
MD20160052A2 (ro
MD4635B1 (ro
Inventor
Эрик КАРЛСОН
Ханс ХАНСЕН
Мэтью МЭКИ
Шон ШИЛЛЕР
Чикако ОГАВА
Хизер ДЭВИС
Ацуси ЭНДО
Линн ХОУКИНС
Салли ИСИДЗАКА
Original Assignee
Eisai R&D Management Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co., Ltd. filed Critical Eisai R&D Management Co., Ltd.
Publication of MD20160052A2 publication Critical patent/MD20160052A2/ro
Publication of MD4635B1 publication Critical patent/MD4635B1/ro
Publication of MD4635C1 publication Critical patent/MD4635C1/ro

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Quinoline Compounds (AREA)

Abstract

Variantele de realizare a invenţiei se referă la compuşi de chinolină substituiţi selectiv, care acţionează ca antagonişti sau inhibitori ai receptorilor Toll-similari (TLR) 7 şi/sau 8, precum şi la utilizarea lor în compoziţii farmaceutice, eficiente pentru tratamentul lupusului eritematos sistemic (LES) şi nefritei lupice.Secvenţe: 2
MDA20160052A 2013-10-14 2014-10-14 Compuşi de chinolină substituiţi selectiv MD4635C1 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361890718P 2013-10-14 2013-10-14
PCT/US2014/060418 WO2015057659A1 (en) 2013-10-14 2014-10-14 Selectively substituted quinoline compounds

Publications (3)

Publication Number Publication Date
MD20160052A2 MD20160052A2 (ro) 2016-09-30
MD4635B1 MD4635B1 (ro) 2019-06-30
MD4635C1 true MD4635C1 (ro) 2020-01-31

Family

ID=51842881

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20160052A MD4635C1 (ro) 2013-10-14 2014-10-14 Compuşi de chinolină substituiţi selectiv

Country Status (35)

Country Link
US (5) US9428495B2 (ro)
EP (3) EP3057964B1 (ro)
JP (3) JP6223563B2 (ro)
KR (2) KR102103256B1 (ro)
CN (2) CN110105346B (ro)
AR (1) AR098014A1 (ro)
AU (2) AU2014334554B2 (ro)
BR (1) BR112016008359B1 (ro)
CA (1) CA2927510C (ro)
CL (1) CL2016000662A1 (ro)
CY (1) CY1122776T1 (ro)
DK (1) DK3057964T3 (ro)
ES (1) ES2773303T3 (ro)
HR (1) HRP20200147T1 (ro)
HU (1) HUE048706T2 (ro)
IL (2) IL245131B (ro)
JO (1) JO3554B1 (ro)
LT (1) LT3057964T (ro)
MA (1) MA39034B1 (ro)
MD (1) MD4635C1 (ro)
MX (2) MX364657B (ro)
MY (1) MY192489A (ro)
PE (1) PE20160608A1 (ro)
PH (1) PH12016500642A1 (ro)
PL (1) PL3057964T3 (ro)
PT (1) PT3057964T (ro)
RS (1) RS59911B1 (ro)
RU (1) RU2679622C2 (ro)
SG (3) SG10202103278TA (ro)
SI (1) SI3057964T1 (ro)
SM (1) SMT202000076T1 (ro)
TW (2) TWI702218B (ro)
UA (1) UA120039C2 (ro)
WO (1) WO2015057659A1 (ro)
ZA (4) ZA201601882B (ro)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104169258B (zh) * 2011-12-22 2017-03-01 默克专利有限公司 用作激酶活性调节剂的新颖的杂环羧酰胺
EP3057964B1 (en) * 2013-10-14 2019-12-04 Eisai R&D Management Co., Ltd. Selectively substituted quinoline compounds
JP6483666B2 (ja) 2013-10-14 2019-03-13 エーザイ・アール・アンド・ディー・マネジメント株式会社 選択的に置換されたキノリン化合物
SMT202400141T1 (it) * 2015-12-17 2024-05-14 Merck Patent Gmbh 8-ciano-5-piperidino-chinoline come antagonisti di tlr7/8 e loro usi per trattamento di disturbi immunitari
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
AU2017307208B2 (en) 2016-07-30 2021-01-21 Bristol-Myers Squibb Company Dimethoxyphenyl substituted indole compounds as TLR7, TLR8 or TLR9 inhibitors
CN109563075B (zh) * 2016-08-08 2022-09-30 默克专利股份公司 Tlr7/8拮抗剂及其用途
JP7028861B2 (ja) * 2016-09-09 2022-03-02 ブリストル－マイヤーズ スクイブ カンパニー ピリジル置換のインドール化合物
NZ750781A (en) * 2016-09-09 2025-06-27 Novartis Ag Compounds and compositions as inhibitors of endosomal toll-like receptors
CN117402852A (zh) 2016-10-14 2024-01-16 精密生物科学公司 对乙肝病毒基因组中的识别序列特异性的工程化大范围核酸酶
JP7239554B2 (ja) 2017-07-18 2023-03-14 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｔｌｒ７／８アンタゴニストおよびそれらの使用
ES2909401T3 (es) 2017-08-04 2022-05-06 Bristol Myers Squibb Co Compuestos de indol sustituidos útiles como inhibidores de TLR7/8/9
CN110997670B (zh) 2017-08-04 2022-11-01 百时美施贵宝公司 [1,2,4]三唑并[4,3-a]吡啶基取代的吲哚化合物
CN111542515B (zh) * 2017-10-30 2023-12-05 科罗拉多州立大学董事会法人团体 Toll样受体8(tlr8)特异性拮抗剂及其制备方法和用途
KR102849449B1 (ko) 2017-11-14 2025-08-21 브리스톨-마이어스 스큅 컴퍼니 치환된 인돌 화합물
BR112020011668A2 (pt) 2017-12-15 2020-11-17 Bristol-Myers Squibb Company compostos de éter de indol substituído
WO2019125977A1 (en) 2017-12-18 2019-06-27 Bristol-Myers Squibb Company 4-azaindole compounds
EP3728229A1 (en) * 2017-12-19 2020-10-28 Merck Patent GmbH Tlr7/8 antagonists and uses thereof
SG11202005700SA (en) 2017-12-19 2020-07-29 Bristol Myers Squibb Co Amide substituted indole compounds useful as tlr inhibitors
CA3085761A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Triazole n-linked carbamoylcyclohexyl acids as lpa antagonists
EP3728225B1 (en) 2017-12-19 2022-11-09 Bristol-Myers Squibb Company Substituted indole compounds useful as tlr inhibitors
BR112020011984A2 (pt) 2017-12-20 2020-11-17 Bristol-Myers Squibb Company compostos de amino indol úteis como inibidores de tlr
EP3728188B1 (en) 2017-12-20 2023-10-11 Bristol-Myers Squibb Company Aryl and heteroaryl substituted indole compounds
SG11202005733QA (en) 2017-12-20 2020-07-29 Bristol Myers Squibb Co Diazaindole compounds
AU2018392212B9 (en) 2017-12-20 2021-03-18 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
AU2018392213B2 (en) 2017-12-20 2021-03-04 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
CN108101860B (zh) * 2018-02-08 2021-11-23 苏州敬业医药化工有限公司 顺式-2，6-二甲基吗啉的制备方法
CN111699187A (zh) 2018-02-12 2020-09-22 豪夫迈·罗氏有限公司 用于治疗和预防病毒感染的新的砜化合物和衍生物
JP7050165B2 (ja) 2018-02-26 2022-04-07 ギリアード サイエンシーズ， インコーポレイテッド Ｈｂｖ複製阻害剤としての置換ピロリジン化合物
CN112119072A (zh) 2018-03-20 2020-12-22 普莱希科公司 用于ido和tdo调节的化合物和方法，以及其适应症
WO2019195181A1 (en) 2018-04-05 2019-10-10 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TW201945388A (zh) 2018-04-12 2019-12-01 美商精密生物科學公司 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶
TW202014193A (zh) 2018-05-03 2020-04-16 捷克科學院有機化學與生物化學研究所 包含碳環核苷酸之2’3’－環二核苷酸
MA52747A (fr) * 2018-06-05 2021-04-14 Hoffmann La Roche Composés tétrahydro-1h-pyrazino[2,1-ajisoindolylquinoline pour le traitement d'une maladie auto-immune
EP3805203A4 (en) * 2018-06-07 2022-02-23 Daiichi Sankyo Company, Limited AZETIDE DERIVATIVE AND PRODRUG THEREOF
TW202016105A (zh) * 2018-06-12 2020-05-01 瑞士商赫孚孟拉羅股份公司 用於治療自體免疫疾病的新穎雜芳基雜環基化合物
JP2021527100A (ja) * 2018-06-13 2021-10-11 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 自己免疫疾患の処置のためのピリジニルヘテロシクリル化合物
AU2019297362B2 (en) * 2018-07-06 2022-05-26 Gilead Sciences, Inc. Therapeutic heterocyclic compounds
WO2020020800A1 (en) 2018-07-23 2020-01-30 F. Hoffmann-La Roche Ag Novel piperazine compounds for the treatment of autoimmune disease
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
EP3847169A1 (en) * 2018-09-04 2021-07-14 F. Hoffmann-La Roche AG Benzothiazole compounds for the treatment of autoimmune diseases
CN112654618A (zh) * 2018-09-06 2021-04-13 豪夫迈·罗氏有限公司 用于治疗自身免疫性疾病的新型环脒化合物
WO2020048596A1 (en) 2018-09-06 2020-03-12 F. Hoffmann-La Roche Ag Novel pyrazolopyridine compounds for the treatment of autoimmune disease
EP3847165A1 (en) * 2018-09-07 2021-07-14 F. Hoffmann-La Roche AG Novel pyrrolidine amine compounds for the treatment of autoimmune disease
CN112673007A (zh) * 2018-09-11 2021-04-16 豪夫迈·罗氏有限公司 用于治疗自身免疫性疾病的吡唑并吡啶胺化合物
EP3623369B1 (en) 2018-09-12 2023-10-25 F. Hoffmann-La Roche AG Novel morpholinyl amine compounds for the treatment of autoimmune disease
WO2020064792A1 (en) 2018-09-27 2020-04-02 F. Hoffmann-La Roche Ag Heterocyclyl compounds for the treatment of autoimmune disease
US11998537B2 (en) 2018-10-24 2024-06-04 Bristol-Myers Squibb Company Substituted indole dimer compounds
EP3870583A1 (en) 2018-10-24 2021-09-01 Bristol-Myers Squibb Company Substituted indole and indazole compounds
SG11202103839UA (en) 2018-10-31 2021-05-28 Gilead Sciences Inc Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
KR102658602B1 (ko) 2018-10-31 2024-04-19 길리애드 사이언시즈, 인코포레이티드 Hpk1 억제 활성을 갖는 치환된 6-아자벤즈이미다졸 화합물
TW202031650A (zh) * 2018-11-09 2020-09-01 瑞士商赫孚孟拉羅股份公司 用於治療自體免疫疾病之吡唑化合物
US11807622B2 (en) 2019-01-30 2023-11-07 Insilico Medicine Ip Limited TLR 9 inhibitors
CA3129022C (en) 2019-03-07 2023-08-01 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides and prodrugs thereof
EP3935065A1 (en) 2019-03-07 2022-01-12 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
CA3129011C (en) 2019-03-07 2023-12-19 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
WO2020227484A1 (en) 2019-05-09 2020-11-12 Bristol-Myers Squibb Company Substituted benzimidazolone compounds
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
US20220296619A1 (en) 2019-08-19 2022-09-22 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
US20220363665A1 (en) 2019-09-10 2022-11-17 Hoffmann-La Roche Inc. Quinoline compounds for the treatment of autoimmune disease
WO2021061204A1 (en) * 2019-09-23 2021-04-01 Accutar Biotechnology Inc. Novel substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereof
KR20220074917A (ko) 2019-09-30 2022-06-03 길리애드 사이언시즈, 인코포레이티드 Hbv 백신 및 hbv를 치료하는 방법
KR20220075381A (ko) 2019-10-01 2022-06-08 브리스톨-마이어스 스큅 컴퍼니 치환된 비시클릭 헤테로아릴 화합물
ES2965164T3 (es) 2019-10-04 2024-04-11 Bristol Myers Squibb Co Compuestos de carbazol sustituidos
EP4051387B1 (en) 2019-10-31 2025-02-19 F. Hoffmann-La Roche AG Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease
US12486273B2 (en) 2019-11-19 2025-12-02 Hoffmann-La Roche Inc. Hydro-1H-pyrrolo[1,2-a]pyrazine compounds for the treatment of autoimmune disease
CN114667286A (zh) 2019-11-19 2022-06-24 豪夫迈·罗氏有限公司 用于治疗自身免疫性疾病的三氮杂三环类化合物
CN114728988B (zh) * 2019-11-20 2024-12-10 豪夫迈·罗氏有限公司 用于治疗自身免疫性疾病的螺(异苯并呋喃氮杂环丁烷)化合物
CN114761406B (zh) * 2019-12-03 2024-04-19 豪夫迈·罗氏有限公司 用于治疗自身免疫性疾病的氢吡啶并[1,2-a]吡嗪化合物
US20230097700A1 (en) * 2019-12-06 2023-03-30 Daiichi Sankyo Company, Limited Azetidine sulfonamide compound
WO2021113765A1 (en) 2019-12-06 2021-06-10 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
KR20220156884A (ko) 2020-03-20 2022-11-28 길리애드 사이언시즈, 인코포레이티드 4'-c-치환된-2-할로-2'-데옥시아데노신 뉴클레오시드의 프로드러그 및 이의 제조 및 사용 방법
CN114685491B (zh) * 2020-12-31 2024-01-12 清华大学 吡啶-2-胺衍生物及其药物组合物和用途
CR20230478A (es) 2021-04-16 2023-11-30 Gilead Sciences Inc Compuestos de tienopirrol.
WO2022241134A1 (en) 2021-05-13 2022-11-17 Gilead Sciences, Inc. COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
WO2022261404A1 (en) * 2021-06-11 2022-12-15 Neuronascent, Inc. Methods and compositions for lipid formulation of lipophilic small molecule therapies of the heterocyclic type
KR20240005901A (ko) 2021-06-23 2024-01-12 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
AU2022298639C1 (en) 2021-06-23 2025-07-17 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
JP7654118B2 (ja) 2021-06-23 2025-03-31 ギリアード サイエンシーズ， インコーポレイテッド ジアシルグリセロールキナーゼ調節化合物
KR20240025616A (ko) 2021-06-23 2024-02-27 길리애드 사이언시즈, 인코포레이티드 다이아실글리세롤 키나제 조절 화합물
KR20240056747A (ko) 2021-09-10 2024-04-30 길리애드 사이언시즈, 인코포레이티드 티에노피롤 화합물
US20250345389A1 (en) 2024-05-13 2025-11-13 Gilead Sciences, Inc. Combination therapies
WO2025240246A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
US20250345390A1 (en) 2024-05-13 2025-11-13 Gilead Sciences, Inc. Combination therapies
WO2025240242A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin

Family Cites Families (168)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO156828C (no) 1980-11-10 1987-12-02 Otsuka Pharma Co Ltd Analogifremgangsm te for fremstilling av antibakterielt virksomme benzoheterocykliske forbindelser.
IL62783A (en) 1981-05-04 1987-01-30 Usv Pharma Corp Antihypertensive 1,4-thiazine,1,4-thiazepine and 1,4-thiazocine compounds,method for the preparation thereof and pharmaceutical compositions containing the same
JPS5890511A (ja) 1981-11-25 1983-05-30 Otsuka Pharmaceut Co Ltd 抗菌剤
US5358949A (en) 1986-03-05 1994-10-25 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives
JPS6354363A (ja) 1986-08-26 1988-03-08 Ss Pharmaceut Co Ltd キノリン誘導体
AU639529B2 (en) 1987-03-04 1993-07-29 Higuchi, Yoshinari Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives
US4933447A (en) 1987-09-24 1990-06-12 Ss Pharmaceutical Co., Ltd. Quinoline derivatives
JPH08295690A (ja) 1995-04-26 1996-11-12 Tokuyama Corp クロメン化合物
EP0952832B1 (en) * 1996-05-20 2008-08-27 Darwin Discovery Limited Quinoline carboxamides as tnf inhibitors and as pde-iv inhibitors
DE69738907D1 (de) 1996-10-11 2008-09-25 Kowa Co Neue diamidverbindungen und medikamente die diese enthalten
DE19643048A1 (de) 1996-10-18 1998-04-23 Daimler Benz Ag Verbindungen und deren Verwendung sowie Verfahren zur Herstellung von flüssigkristallinen Polymeren daraus
GB9712761D0 (en) 1997-06-17 1997-08-20 Chiroscience Ltd Quinolines and their therapeutic use
US6933272B1 (en) 1998-09-22 2005-08-23 Erik Helmerhorst Use of non-peptidyl compounds for the treatment of insulin related ailments
AU782404B2 (en) 1999-04-28 2005-07-28 Sanofi-Aventis Deutschland Gmbh Tri-aryl acid derivatives as PPAR receptor ligands
YU72201A (sh) 1999-04-28 2005-07-19 Aventis Pharma Deutschland Gmbh. Derivati di-aril kiseline kao ppar receptorski ligandi
DE19936437A1 (de) 1999-08-03 2001-02-08 Aventis Cropscience Gmbh Kombinationen aus Herbiziden und Safenern
US6710205B2 (en) 2000-02-22 2004-03-23 Ono Pharmaceutical Co., Ltd. Benzoic acid derivatives, processes for producing the same and drugs containing the same as the active ingredient
IL151018A0 (en) 2000-03-17 2003-02-12 Bristol Myers Squibb Pharma Co Beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha
EP1263755A2 (en) 2000-03-17 2002-12-11 Bristol-Myers Squibb Pharma Company Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha
AU2001280187A1 (en) 2000-08-28 2002-03-13 Toray Industries, Inc. Cyclic amine derivatives
ATE309996T1 (de) 2000-09-11 2005-12-15 Chiron Corp Chinolinonderivate als tyrosin-kinase inhibitoren
US20030028018A1 (en) 2000-09-11 2003-02-06 Chiron Coporation Quinolinone derivatives
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
EP1371376A4 (en) 2001-03-19 2009-03-25 Nippon Shinyaku Co Ltd Antipruritic agents
US20030055263A1 (en) 2001-07-11 2003-03-20 Boehringer Ingelheim Pharma Kg Carboxylic acid derivatives, medicaments comprising these compounds, their use and processes for their production
US6897220B2 (en) 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
CN101851173A (zh) 2001-09-14 2010-10-06 梅特希尔基因公司 组蛋白脱乙酰化酶抑制剂
US7868204B2 (en) 2001-09-14 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
DE10222166A1 (de) 2002-05-20 2003-12-11 Fraunhofer Ges Forschung Chirale Verbindungen und deren Verwendung
DE10229070A1 (de) 2002-06-28 2004-01-15 Merck Patent Gmbh Phenylderivate 5
US7358249B2 (en) 2002-08-13 2008-04-15 Shionogi & Co., Ltd. Heterocyclic compounds having inhibitory activity against HIV integrase
US20050256157A1 (en) 2002-08-23 2005-11-17 Chiron Corporation Combination therapy with CHK1 inhibitors
US7825132B2 (en) 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
EP1539754A4 (en) 2002-08-23 2009-02-25 Novartis Vaccines & Diagnostic BENZIMIDAZOCHINOLINONE AND ITS USE
US7041693B2 (en) 2002-10-04 2006-05-09 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE)
AU2003284001A1 (en) 2002-10-07 2004-05-04 Bristol-Myers Squibb Company Triazolone and triazolethione derivatives
US20040072802A1 (en) 2002-10-09 2004-04-15 Jingwu Duan Beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha
GB2396154B (en) 2002-10-15 2007-02-28 Merck Patent Gmbh 4,5-Dicyanoimidazole derivatives and their use in liquid crystal media and liquid crystal devices
US7442475B2 (en) 2003-02-22 2008-10-28 Merck Patent Gmbh Cyanopyridone derivatives as liquid crystals
AU2004221812B2 (en) 2003-03-19 2010-02-18 Exelixis Inc. Tie-2 modulators and methods of use
AU2004225965A1 (en) 2003-03-25 2004-10-14 Vertex Pharmaceuticals Incorporated Thiazoles useful as inhibitors of protein kinases
WO2004087835A1 (en) 2003-04-01 2004-10-14 Merck Patent Gmbh Chiral polymerizable compounds
ZA200510028B (en) * 2003-06-20 2007-03-28 Coley Pharm Gmbh Small molicule toll-like receptor (TLR) antagonists
CA2528774A1 (en) 2003-06-20 2005-01-27 Coley Pharmaceutical Gmbh Small molecule toll-like receptor (tlr) antagonists
WO2005028488A1 (en) 2003-09-12 2005-03-31 Quatrx Pharmaceuticals Co. Heteroaryl phosphinyl and thiophosphinyl compounds for regulation of glucose, triglycerides, and ldl/hdl levels
US7211671B2 (en) 2003-10-01 2007-05-01 Bristol Myers Squibb Company Substituted 1,3-dihydro-imidazol-2-one and 1,3-dihydro-imidazol-2-thione derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE)
JP2005132834A (ja) * 2003-10-09 2005-05-26 Kyowa Hakko Kogyo Co Ltd キノリン誘導体
CN1291977C (zh) * 2003-10-20 2006-12-27 复旦大学 多取代喹啉衍生物功能材料及其制备方法和应用
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
WO2005046590A2 (en) 2003-11-07 2005-05-26 Chiron Corporation Methods for synthesizing quinolinone compounds
TWI316955B (en) 2003-11-19 2009-11-11 Chisso Corp Photo-polymerization liquid composition,polymer or polymer co mposition and optical compensation device thereof
EP1713810B1 (en) 2004-02-04 2010-12-29 NeuroSearch A/S Diazabicyclic aryl derivatives as nicotinic acetylcholine receptor ligands
TW200604183A (en) 2004-02-18 2006-02-01 Astrazeneca Ab Triazole compounds and their use as metabotropic glutamate receptor antagonists
JP5019884B2 (ja) 2004-02-20 2012-09-05 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 炎症プロセスおよび転移プロセスの調節
WO2005087217A1 (en) 2004-03-05 2005-09-22 The General Hospital Corporation Compositions and methods for modulating interaction between polypeptides
WO2005108370A1 (ja) 2004-04-16 2005-11-17 Ajinomoto Co., Inc. ベンゼン化合物
CN101248069A (zh) 2004-05-17 2008-08-20 阿卡蒂亚药品公司 雄激素受体调节剂及用其治疗疾病的方法
US20070004679A1 (en) 2004-05-17 2007-01-04 Nathalie Schlienger Androgen receptor modulators and methods of treating disease using the same
US7514450B2 (en) 2004-05-19 2009-04-07 Neurosearch A/S Azabicyclic aryl derivatives
GB0418046D0 (en) 2004-08-12 2004-09-15 Prosidion Ltd Eantioselective process
DE102004039789A1 (de) 2004-08-16 2006-03-02 Sanofi-Aventis Deutschland Gmbh Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
GB0510143D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
US20080306055A1 (en) 2004-12-21 2008-12-11 Astrazeneca Ab Heterocyclic Mchr1 Antagonists And Their Use In Therapy
US7880002B2 (en) 2004-12-29 2011-02-01 Millennium Pharmaceuticals, Inc. Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists
US7317024B2 (en) 2005-01-13 2008-01-08 Bristol-Myers Squibb Co. Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
WO2006110276A2 (en) 2005-04-08 2006-10-19 Cropsolution, Inc. Acylated thiosemicarbazides as herbicides
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
CN101213201A (zh) 2005-06-30 2008-07-02 比奥纽默里克药物公司 单亚胺配体铂类似物
JP2007045752A (ja) 2005-08-10 2007-02-22 Takeda Chem Ind Ltd ５員芳香族複素環誘導体、その製造法および用途
JP2007131765A (ja) 2005-11-11 2007-05-31 Fujifilm Corp 液晶性組成物
NZ569817A (en) 2005-12-21 2011-10-28 Abbott Lab Anti-viral compounds
US20070254894A1 (en) 2006-01-10 2007-11-01 Kane John L Jr Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation
US20100222353A1 (en) 2006-01-27 2010-09-02 Pfizer Products Inc. Aminophthalazine derivative compounds
PL2044056T3 (pl) 2006-07-14 2013-01-31 Novartis Ag Pochodne pirymidyny jako inhibitory ALK-5
US7683060B2 (en) 2006-08-07 2010-03-23 Incyte Corporation Triazolotriazines as kinase inhibitors
EP1900731A1 (de) 2006-09-07 2008-03-19 Bayer Schering Pharma Aktiengesellschaft N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren
US7902363B2 (en) 2006-11-17 2011-03-08 Polyera Corporation Diimide-based semiconductor materials and methods of preparing and using the same
KR20090122396A (ko) * 2007-03-22 2009-11-27 아스트라제네카 아베 염증성 질환 치료용 퀴놀린 유도체
DE102007015169A1 (de) 2007-03-27 2008-10-02 Universität des Saarlandes Campus Saarbrücken 17Beta-Hydroxysteroid-Dehydrogenase-Typ1-Inhibitoren zur Behandlung hormonabhängiger Erkrankungen
ES2470341T3 (es) 2007-04-05 2014-06-23 Amgen, Inc Moduladores de la aurora cinasa y método de uso
WO2008131779A1 (en) 2007-04-26 2008-11-06 H. Lundbeck A/S Isoquinolinone derivatives as nk3 antagonists
US8173639B2 (en) 2007-04-26 2012-05-08 H. Lundbeck A/S Isoquinolinone derivatives as NK3 antagonists
US8557823B2 (en) 2007-06-18 2013-10-15 Advanced Cancer Therapeutics, Llc Family of PFKFB3 inhibitors with anti-neoplastic activities
US8088385B2 (en) 2007-06-18 2012-01-03 University Of Louisville Research Foundation Inc. PFKB3 inhibitor for the treatment of a proliferative cancer
CA2689575A1 (en) 2007-06-20 2008-12-24 Merck Sharp & Dohme Corp. Cetp inhibitors derived from benzoxazole arylamides
JP2010530417A (ja) 2007-06-20 2010-09-09 メルク・シャープ・エンド・ドーム・コーポレイション ベンゾオキサゾールアリールアミドから誘導されたｃｅｔｐ阻害剤
JP5057056B2 (ja) 2007-08-03 2012-10-24 Ｊｓｒ株式会社 液晶配向剤、液晶配向膜の製造方法、ポリアミック酸およびポリイミドならびにジアミン化合物
JP2009108152A (ja) 2007-10-29 2009-05-21 Sumitomo Chemical Co Ltd 重合性化合物および光学フィルム
CN101910164A (zh) 2007-10-29 2010-12-08 先灵公司 作为蛋白质激酶抑制剂的二酰氨基噻唑衍生物
CN101440062B (zh) 2007-11-23 2011-09-28 齐齐哈尔大学 N-酰基-8-氨基喹啉衍生物的合成及其作为荧光分子探针的应用
JP2009149754A (ja) 2007-12-20 2009-07-09 Sumitomo Chemical Co Ltd 重合性化合物および該重合性化合物を重合してなる光学フィルム
CA2715842A1 (en) 2008-03-07 2009-09-11 F. Hoffmann-La Roche Ag 2-aminoquinoline derivatives
JP5219583B2 (ja) 2008-03-31 2013-06-26 住友化学株式会社 組成物、光学フィルムとその製造方法、光学部材及び表示装置
US8980877B2 (en) 2008-04-15 2015-03-17 Dac S.R.L. Spirocyclic derivatives as histone deacetylase inhibitors
US8703811B2 (en) 2008-05-07 2014-04-22 Genzyme Corporation Small molecule inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase
WO2009139438A1 (ja) 2008-05-15 2009-11-19 田辺三菱製薬株式会社 光学活性カルボン酸の製造方法
AU2009257372A1 (en) 2008-06-11 2009-12-17 Irm Llc Compounds and compositions useful for the treatment of malaria
WO2009152025A1 (en) 2008-06-11 2009-12-17 Merck & Co., Inc. Imidazole derivatives useful as inhibitors of faah
WO2009151991A1 (en) 2008-06-11 2009-12-17 Merck & Co., Inc. Pyrazole derivatives useful as inhibitors of faah
US8822513B2 (en) 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
LT3289876T (lt) 2008-06-16 2022-11-10 University Of Tennessee Research Foundation Junginiai, skirti vėžio gydymui
WO2010010187A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
BRPI0916713A2 (pt) 2008-07-28 2015-11-10 Gilead Science Inc compostos inibidores de histona desacetilase de cicloalquilideno e heterocicloalquilideno
WO2010017079A1 (en) 2008-08-04 2010-02-11 Merck & Co., Inc. Oxazole derivatives useful as inhibitors of faah
WO2010018874A1 (en) 2008-08-12 2010-02-18 Takeda Pharmaceutical Company Limited Amide compound
JP5443720B2 (ja) 2008-09-05 2014-03-19 住友化学株式会社 組成物、光学フィルム及びその製造方法、光学部材ならびに表示装置
JP2010066630A (ja) 2008-09-12 2010-03-25 Sumitomo Chemical Co Ltd 光学フィルムの製造方法及び光学フィルム
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
JP5544366B2 (ja) 2008-10-23 2014-07-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換ノルトロパンの尿素誘導体、該化合物を含有する医薬及びその使用
US8987242B2 (en) 2008-12-05 2015-03-24 Merck Sharp & Dohme Corp. Morpholinone compounds as factor IXA inhibitors
US8642582B2 (en) 2008-12-05 2014-02-04 Merck Sharp & Dohme Corp. Morpholinone compounds as factor IXa inhibitors
CN102245604A (zh) 2008-12-23 2011-11-16 雅培制药有限公司 抗病毒化合物
EP2367824B1 (en) 2008-12-23 2016-03-23 AbbVie Inc. Anti-viral derivatives of pyrimidine
CN101759683B (zh) 2008-12-25 2011-12-28 哈尔滨誉衡药业股份有限公司 二氢化茚酰胺化合物制备方法、包含其的药物组合物、及其作为蛋白激酶抑制剂的应用
US8889670B2 (en) 2009-02-18 2014-11-18 Boehringer Ingelheim International Gmbh Heterocyclic compounds which modulate the CB2 receptor
JP5899607B2 (ja) 2009-03-16 2016-04-06 住友化学株式会社 化合物、光学フィルム及び光学フィルムの製造方法
CN104592219B (zh) 2009-03-16 2017-04-12 住友化学株式会社 化合物、光学膜和光学膜的制造方法
JP2011008205A (ja) 2009-05-27 2011-01-13 Fujifilm Corp 二軸性光学異方性膜を作製するための組成物
JP2011006360A (ja) 2009-06-26 2011-01-13 Sumitomo Chemical Co Ltd 化合物、光学フィルム及び光学フィルムの製造方法
GB0912777D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydropyrimidone derivatives
US20110021531A1 (en) 2009-07-27 2011-01-27 Chobanian Harry Oxazole derivatives useful as inhibitors of faah
US9212177B2 (en) 2009-08-05 2015-12-15 Versitech Limited Antiviral compounds and methods of making and using thereof
CN102573994B (zh) 2009-08-06 2015-06-24 默克专利有限公司 双环脲化合物
JP2011042606A (ja) 2009-08-20 2011-03-03 Sumitomo Chemical Co Ltd 化合物、光学フィルム及び光学フィルムの製造方法
US8669259B2 (en) 2009-08-26 2014-03-11 Merck Sharp & Dohme Corp. Heterocyclic amide compounds as protein kinase inhibitors
EP2473491B1 (en) 2009-08-31 2013-07-17 Mochida Pharmaceutical Co., Ltd. Morpholinone compounds as factor ixa inhibitors
TWI499592B (zh) 2009-09-09 2015-09-11 Avila Therapeutics Inc Ｐｉ３激酶抑制劑及其用途
KR20120078715A (ko) 2009-09-10 2012-07-10 노파르티스 아게 암의 치료를 위한 ｂｃｌ-2군 단백질의 억제제로서의 술폰아미드
KR101746250B1 (ko) 2009-12-01 2017-06-12 스미또모 가가꾸 가부시키가이샤 시클로알칸디카르복실산 모노에스테르의 제조 방법
KR20120118008A (ko) 2009-12-18 2012-10-25 아이데닉스 파마슈티칼스, 인코포레이티드 5,5-융합 아릴렌 또는 헤테로아릴렌 간염 ｃ 바이러스 억제제
JP2013517281A (ja) 2010-01-13 2013-05-16 テンペロ、ファーマシューティカルズ、インコーポレイテッド 化合物及び方法
MX341133B (es) 2010-01-13 2016-08-08 Tempero Pharmaceuticals Inc * Compuestos y metodos para la inhibición de hdac.
US20130030000A1 (en) 2010-01-28 2013-01-31 Chobanian Harry R Pharmaceutical compositions for the treatment of pain and other indications
BR112012020273A8 (pt) 2010-02-11 2017-12-26 Univ Vanderbilt compostos de pirazolopiridina, pirazolopirazina, pirazolopirimidina, pirazolotiofeno e pirazolotiazol como pontencializadores alostéricos de mglur4, composições e métodos de tratamento de disfunção neurológica
JP5879273B2 (ja) 2010-03-01 2016-03-08 ジーティーエックス・インコーポレイテッド 癌を処置するための化合物
JP5871896B2 (ja) 2010-03-26 2016-03-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂ−ｒａｆキナーゼインヒビター
JP5871897B2 (ja) 2010-03-26 2016-03-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ピリジルトリアゾール
WO2011133871A2 (en) 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. 5'-end derivatives
CA2794724A1 (en) 2010-04-22 2011-10-27 Merck Sharp & Dohme Corp. Oxazole derivatives useful as modulators of faah
AU2011242688B2 (en) 2010-04-23 2015-01-22 Kineta, Inc. Anti-viral compounds
US8895608B2 (en) 2010-04-23 2014-11-25 Kineta, Inc. Sulfonamide anti-viral compounds
US20120149715A1 (en) 2010-05-28 2012-06-14 Yi Tsun Richard Kao Compounds and methods for the treatment of viral infections
JP5652011B2 (ja) 2010-06-10 2015-01-14 住友化学株式会社 光学フィルム
EP2593107A1 (en) 2010-07-12 2013-05-22 Merck Sharp & Dohme Corp. Tyrosine kinase inhibitors
WO2012016133A2 (en) 2010-07-29 2012-02-02 President And Fellows Of Harvard College Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
JP5862669B2 (ja) 2010-08-26 2016-02-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン産生のオキサジアゾール阻害剤
WO2012033390A2 (en) 2010-09-10 2012-03-15 Green Cross Corporation Novel thiophene derivative as sglt2 inhibitor and pharmaceutical composition comprising same
JP2013540145A (ja) 2010-10-21 2013-10-31 ウニベルシテート デス ザールランデス コルチゾール依存性疾患の治療用の選択的ｃｙｐ１１ｂ１阻害剤
EP2632898A4 (en) 2010-10-29 2014-04-02 Biogen Idec Inc HETEROCYCLIC TYROSINE KINASE HEMMER
US8710055B2 (en) 2010-12-21 2014-04-29 Boehringer Ingelheim International Gmbh Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors
KR20140015279A (ko) 2010-12-23 2014-02-06 솔베이(소시에떼아노님) 트리스 동종리간드 금속 착물을 위한 fac-이성질체의 제조
US20120214803A1 (en) 2011-02-18 2012-08-23 Vifor (International) Ag Novel Sulfonaminoquinoline Hepcidin Antagonists
MX347982B (es) 2011-03-14 2017-05-22 Vertex Pharma Morfolina-piperidina espirociclica-amidas como moduladores de canales ionicos.
CN102675289B (zh) 2011-03-18 2014-11-05 浙江大德药业集团有限公司 作为蛋白激酶抑制剂的n-苯基苯甲酰胺衍生物
WO2012128582A2 (en) 2011-03-23 2012-09-27 Hyundai Pharm Co., Ltd. A COMPOUND FOR INHIBITING HUMAN 11-β-HYDROXY STEROID DEHYDROGENASE TYPE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
TW201311149A (zh) * 2011-06-24 2013-03-16 Ishihara Sangyo Kaisha 有害生物防治劑
EP2729459B1 (en) 2011-07-07 2018-08-22 Merck Patent GmbH Substituted azaheterocycles for the treatment of cancer
WO2013009830A1 (en) 2011-07-13 2013-01-17 Tempero Pharmaceuticals, Inc. Methods of treatment
WO2013009810A1 (en) 2011-07-13 2013-01-17 Tempero Pharmaceuticals, Inc. Methods of treatment
WO2013009827A1 (en) 2011-07-13 2013-01-17 Tempero Pharmaceuticals, Inc. Methods of treatment
AU2012311061B2 (en) 2011-09-23 2016-08-18 Advinus Therapeutics Limited Amide compounds, compositions and applications thereof
WO2013071093A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Pyrazine compounds useful as inhibitors of atr kinase
EP2776421A1 (en) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2013071090A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
EP3057964B1 (en) 2013-10-14 2019-12-04 Eisai R&D Management Co., Ltd. Selectively substituted quinoline compounds
JP6483666B2 (ja) 2013-10-14 2019-03-13 エーザイ・アール・アンド・ディー・マネジメント株式会社 選択的に置換されたキノリン化合物

Also Published As

Publication number Publication date
BR112016008359B1 (pt) 2022-07-19
JP2016535003A (ja) 2016-11-10
US20180354939A1 (en) 2018-12-13
CA2927510C (en) 2022-03-01
LT3057964T (lt) 2020-02-25
KR20160068949A (ko) 2016-06-15
MD20160052A2 (ro) 2016-09-30
JP6420878B2 (ja) 2018-11-07
JO3554B1 (ar) 2020-07-05
JP6639607B2 (ja) 2020-02-05
TW201838988A (zh) 2018-11-01
SG10201704327RA (en) 2017-06-29
WO2015057659A1 (en) 2015-04-23
IL245131A0 (en) 2016-06-30
US9428495B2 (en) 2016-08-30
MX2016004632A (es) 2016-10-26
RU2016118619A (ru) 2017-11-22
JP2019023220A (ja) 2019-02-14
US20150105370A1 (en) 2015-04-16
US20180030045A1 (en) 2018-02-01
MY192489A (en) 2022-08-23
KR101823488B1 (ko) 2018-01-30
SI3057964T1 (sl) 2020-03-31
MA39034A1 (fr) 2018-01-31
MA39034B1 (fr) 2018-09-28
AU2018264036B2 (en) 2020-07-16
USRE47193E1 (en) 2019-01-08
IL245131B (en) 2018-11-29
TW201602100A (zh) 2016-01-16
PE20160608A1 (es) 2016-07-08
ZA201905393B (en) 2020-11-25
HRP20200147T1 (hr) 2020-05-01
SG10202103278TA (en) 2021-04-29
PL3057964T3 (pl) 2020-05-18
MX2019005192A (es) 2019-10-21
PT3057964T (pt) 2020-02-25
CN106414432B (zh) 2019-06-14
EP3995495A1 (en) 2022-05-11
CN110105346A (zh) 2019-08-09
CY1122776T1 (el) 2021-05-05
ES2773303T3 (es) 2020-07-10
UA120039C2 (uk) 2019-09-25
EP3057964B1 (en) 2019-12-04
US20160326161A1 (en) 2016-11-10
MD4635B1 (ro) 2019-06-30
RU2679622C2 (ru) 2019-02-12
RS59911B1 (sr) 2020-03-31
CL2016000662A1 (es) 2016-12-16
JP2017226700A (ja) 2017-12-28
CN110105346B (zh) 2023-03-10
TWI702218B (zh) 2020-08-21
JP6223563B2 (ja) 2017-11-01
AR098014A1 (es) 2016-04-27
KR102103256B1 (ko) 2020-04-23
ZA201601882B (en) 2019-09-25
EP3626717A1 (en) 2020-03-25
HUE048706T2 (hu) 2020-08-28
IL262970B (en) 2019-10-31
AU2014334554A1 (en) 2016-06-02
AU2018264036A1 (en) 2018-12-06
PH12016500642B1 (en) 2016-05-30
IL262970A (en) 2018-12-31
SMT202000076T1 (it) 2020-03-13
TWI624467B (zh) 2018-05-21
CA2927510A1 (en) 2015-04-23
RU2016118619A3 (ro) 2018-05-23
US10087174B2 (en) 2018-10-02
MX364657B (es) 2019-05-03
EP3057964A1 (en) 2016-08-24
CN106414432A (zh) 2017-02-15
NZ720129A (en) 2021-03-26
KR20180011874A (ko) 2018-02-02
ZA201801112B (en) 2020-10-28
MX374600B (es) 2025-03-06
HK1223092A1 (en) 2017-07-21
AU2014334554B2 (en) 2018-12-06
BR112016008359A2 (ro) 2017-10-03
ZA201608132B (en) 2019-01-30
SG11201602818TA (en) 2016-05-30
PH12016500642A1 (en) 2016-05-30
DK3057964T3 (da) 2020-02-24

Similar Documents

Publication Publication Date Title
MD4635C1 (ro) Compuşi de chinolină substituiţi selectiv
PH12019500522A1 (en) Tetrahydropyrazolopyrimidine compounds
MX363708B (es) Compuestos de quinolina selectivamente sustituidos.
MX2015008999A (es) Inhibidores mk2 y usos de los mismos.
IL248347A0 (en) Compounds and preparations as agonists of toll-like receptor 7
IL248311B (en) Compounds and preparations as agonists of toll-like receptor 7
UA117470C2 (uk) Заміщені ксантини та способи їх застосування
MX2016003843A (es) Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
MY179781A (en) Biaryl inhibitors of bruton&#39;s tyrosine kinase
PH12015502041B1 (en) Heteroaryl compounds and uses thereof
PH12020500255A1 (en) Use of nk-1 receptor antagonist serlopitant in pruritus
NZ763528A (en) Heterocyclic gpr119 agonist compounds
MX2020001756A (es) Compuestos deuterados del inhibidor vmat y el uso de dichos compuestos.
EA201690523A1 (ru) Триазолопиридины, композиции и способы их применения
IN2013MU03641A (ro)
MA39824A (fr) Composés azole amido-substitués

Legal Events

Date Code Title Description
FG4A Patent for invention issued